Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

The objectives of this study were to estimate the prevalence of Hepatitis C among six Italian Local Health Units (LHUs), to describe patient and antiviral drug characteristics, and to estimate the health care consumption rates and related costs for the management of patients affected by hepatitis C virus (HCV) infection by using data from routine clinical practice

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

[Background] There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.Methods`] A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom. Treatment response was defined as a sustained virologic response (unquantifiable hepatitis C RNA) at 12 weeks post treatment. We summarised the characteristics of the patients in this cohort and estimated the rate of sustained virologic response for patients receiving daclatasvir and sofosbuvir with or without ribavirin using hierarchical Bayesian modelling.[Results] The 249 patients included had a median age of 56 years; most were male (78%), hepatitis C genotype 1 (75%), treatment experienced (65%) and with decompensated cirrhosis (59%). Many had had a liver transplant before receiving daclatasvir (40%). Of the 249 patients, 242 patients received daclatasvir and sofosbuvir and either reached 12 weeks post treatment or died during (n = 9) or after treatment (n = 4) or were lost to follow up during treatment (n = 1). The estimated rate of sustained virologic response at 12 weeks post treatment was 87% (95% credible interval 75 to 94%) for previously treated genotype 1 patients with decompensated cirrhosis.[Conclusions] Daclatasvir with sofosbuvir is an effective treatment in clinical practice for hepatitis C genotype 1 patients with decompensated cirrhosis.This work was supported by BMS.Peer reviewe

Les environnements résidentiels et l'obésité (l'application de techniques d'appariement pour estimer les relations)

Face aux inégalités géographiques de prévalence d obésité rapportées dans la littérature, et au manque d études réalisées en France, nous nous sommes intéressés dans le cadre de cette thèse aux relations empiriques entre les caractéristiques sociodémographiques, physiques, sociales et liées aux services des environnements résidentiels et deux variables anthropométriques, l indice de masse corporelle (IMC) et le tour de taille (TT). Parallèlement à l étude de ces relations, notre objectif méthodologique étant d explorer certains problèmes liés aux techniques d analyses employées, notamment ceux associés à l analyse de variables fortement corrélées. Nous avons observé que les caractéristiques socioéconomiques des environnements résidentiels étaient associées à l IMC et au TT et que ces estimations pouvaient être obtenues sans avoir recours à des extrapolations excessives des modèles de régression, malgré le niveau de ségrégation socio-spatial existant. Nous avons par ailleurs trouvé que certaines caractéristiques physiques et liées aux services de l environnement résidentiel étaient associées au statut pondéral, même s il était impossible de démêler ces effets, du fait des niveaux élevés de corrélation existant entre ces diverses variables environnementales. Il est donc plus prudent de conclure à un effet protecteur global des densités envisagées. Des approches alternatives définissant des typologies de quartiers pourront apporter d autres éléments de réponses à la compréhension de cette thématiquePARIS-BIUSJ-Biologie recherche (751052107) / SudocSudocFranceF

Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

The objectives of this study were to estimate the prevalence of Hepatitis C among six Italian Local Health Units (LHUs), to describe patient and antiviral drug characteristics, and to estimate the health care consumption rates and related costs for the management of patients affected by hepatitis C virus (HCV) infection by using data from routine clinical practice

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

[Background] There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.Methods`] A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom. Treatment response was defined as a sustained virologic response (unquantifiable hepatitis C RNA) at 12 weeks post treatment. We summarised the characteristics of the patients in this cohort and estimated the rate of sustained virologic response for patients receiving daclatasvir and sofosbuvir with or without ribavirin using hierarchical Bayesian modelling.[Results] The 249 patients included had a median age of 56 years; most were male (78%), hepatitis C genotype 1 (75%), treatment experienced (65%) and with decompensated cirrhosis (59%). Many had had a liver transplant before receiving daclatasvir (40%). Of the 249 patients, 242 patients received daclatasvir and sofosbuvir and either reached 12 weeks post treatment or died during (n = 9) or after treatment (n = 4) or were lost to follow up during treatment (n = 1). The estimated rate of sustained virologic response at 12 weeks post treatment was 87% (95% credible interval 75 to 94%) for previously treated genotype 1 patients with decompensated cirrhosis.[Conclusions] Daclatasvir with sofosbuvir is an effective treatment in clinical practice for hepatitis C genotype 1 patients with decompensated cirrhosis.This work was supported by BMS.Peer reviewe